Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The CD4-gp120 interaction is a critical molecular event in the entry process of Human Immunodeficiency Virus type 1 (HIV-1) into host cells. gp120 is the external envelope glycoprotein of HIV-1, while CD4 is a cell surface receptor primarily found on T-helper lymphocytes, monocytes, macrophages, and dendritic cells. The binding of gp120 to CD4 initiates a cascade of conformational changes that are essential for viral entry, including exposure of the co-receptor binding site (CCR5 or CXCR4) and subsequent membrane fusion. This interaction is a key target for therapeutic intervention to prevent HIV infection.
CD4-gp120 interaction is the primary target for entry inhibitors, preventing the virus from attaching to and entering host cells. Blocking this interaction prevents downstream events like coreceptor binding and membrane fusion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD4-gp120 Interaction.